A Hybrid Nanoparticle Probe for Dual‐Modality Positron Emission Tomography and Magnetic Resonance Imaging

Choi, Jinsil; Park, Jeong Chan; Nah, Hyunsoo; Woo, Sung-Ho; Oh, Jong–Hoon; Kim, Kyeong Min; Cheon, Gi Jeong; Chang, Yongmin; Yoo, Jeongsoo; Cheon, Jinwoo

doi:10.1002/ange.200801369

Cited by 60 publications

(76 citation statements)

References 33 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, accurate imaging of SLN is critical for the diagnosis and treatment of metastasis of solid tumors. Choi et al 136 designed a multimodal magnetic nanoparticle-based PET/MRI probe for non-invasive mapping of SLNs (Fig. 8).…”

Section: Pet and Mri Combinationsmentioning

confidence: 99%

Multifunctional Probes for Multimodality Imaging of Cancer

Liu¹,

Chen²,

Ai³

2012

Molecular Imaging Probes for Cancer Research

View full text Add to dashboard Cite

Section: Pet and Mri Combinationsmentioning

confidence: 99%

Multifunctional Probes for Multimodality Imaging of Cancer

Liu¹,

Chen²,

Ai³

2012

Molecular Imaging Probes for Cancer Research

View full text Add to dashboard Cite

“…38,39,148 Radiolabeled 124 I-IO PET/MRI duality modality tumor imaging was also reported. 149 The synthesis and in vivo characterization of an 18 F-labeled trimodal (MRI/PET-CT/optical) IO for tumor imaging, the facile conjugation chemistry provides a simple platform for rapid and efficient IO labeling. 40 Tumor targeting angiogenesis and comparison of 99m Tc-labeled peptide and 99m Tc-labeled polymer-peptide nanocarrier conjugates were investigated.…”

Section: Active Nanotargeting Delivery Of Radionuclides For Nuclear Imentioning

confidence: 99%

Nanotargeted Radiopharmaceuticals for Nuclear Imaging and Radiotherapy

Ting¹,

Tseng²,

Chang³

et al. 2014

Frontiers in Nanobiomedical Research

View full text Add to dashboard Cite

Nanotechnology holds signifi cant promise for improving the development of new and paradigm shift tools for the targeted personalized diagnostics and therapeutics of cancer and other diseases. Current progress in nanotechnology has exploited the possibility of designing tumor-targeted nanocarriers that can deliver radionuclide payloads in a site or molecular selective manner to improve the effi cacy and safety of nuclear imaging and radiotherapy. Radionuclides of auger electron-, α-, β-, γ-and positronemitters have been after-loaded, inserted and surface bioconjugated in nanoparticles (NPs) to improve the effi cacy and to reduce the toxicity in preclinical studies. In addition, the combining of disease-specifi c multifunctional, multimodality and multivalent delivery of nanocarriers will hopefully achieve earlier disease detection and better treatment.The aim of this chapter is to provide an overview of nanotargeted radionuclides, up-to-date research and development, current status of applications, advantages, problems and future prospects and challenges. Two major strategies of passively and actively nanotargeted radiopharmaceuticals with illustrating examples are briefl y reviewed and summarized. Current advances in research of passive targeting co-delivery of radionuclides and chemotherapeutics, and advantages of nanocarriers in multifunctional and multimodality application for nuclear imaging and radiotherapy are discussed. Finally, radiotoxicology/nanotoxicology, clinical research and regulatory issues are also briefl y explored. Research on the combining different modes of selective delivery of radionuclides with targeted nanocarriers offers the new possibility Handbook of Nanobiomedical Research Downloaded from www.worldscientific.com by UNIVERSITY OF TOKYO on 06/05/15. For personal use only. 78 G. Ting et al. of increasing personalized diagnostic effi cacy and radiotherapeutic index. However, further efforts and challenges in preclinical and clinical effi cacy and toxicity studies are required to translate those advanced new technologies to the clinical applications for the healthcare benefi t of the patients.

show abstract

“…To date, radiolabeling strategies resulting in high labeling yield and specific activity have been established for labeling iron oxide nanoparticles with positron emitters such as 64 Cu, 68 ga, and 124 I. The in vivo biodistribution and targeting efficiency of these radiolabeled nanoparticles have been studied in a variety of animal disease models [95][96][97][98]. After coating the iron oxide surface with the carbohydrate dextran and conjugating with DTpA, 64 Cu-radiolabeled iron oxide nanoparticles ( 64 Cu-TNp) were used to target macrophages in an apolipoprotein e-deficient (apoe −/− ) mouse model of aneurysms.…”

Section: Radiolabeled Iron Oxides For Pet Imagingmentioning

confidence: 99%